Black Diamond Therapeutics Inc (NASDAQ: BDTX) has a price-to-earnings ratio that is above its average at 33.39x. The stock has a 36-month beta value of 2.68. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BDTX is 43.30M, and at present, short sellers hold a 21.80% of that float. On May 23, 2025, the average trading volume of BDTX was 3.40M shares.
BDTX) stock’s latest price update
Black Diamond Therapeutics Inc (NASDAQ: BDTX) has seen a rise in its stock price by 1.48 in relation to its previous close of 2.03. However, the company has experienced a 6.74% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-12 that CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update.
BDTX’s Market Performance
Black Diamond Therapeutics Inc (BDTX) has seen a 6.74% rise in stock performance for the week, with a 30.38% gain in the past month and a -4.63% plunge in the past quarter. The volatility ratio for the week is 6.03%, and the volatility levels for the past 30 days are at 5.72% for BDTX. The simple moving average for the past 20 days is 15.07% for BDTX’s stock, with a -28.84% simple moving average for the past 200 days.
Analysts’ Opinion of BDTX
Many brokerage firms have already submitted their reports for BDTX stocks, with Raymond James repeating the rating for BDTX by listing it as a “Outperform.” The predicted price for BDTX in the upcoming period, according to Raymond James is $20 based on the research report published on July 31, 2024 of the previous year 2024.
Stifel gave a rating of “Buy” to BDTX, setting the target price at $10 in the report published on June 30th of the previous year.
BDTX Trading at 25.04% from the 50-Day Moving Average
After a stumble in the market that brought BDTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.48% of loss for the given period.
Volatility was left at 5.72%, however, over the last 30 days, the volatility rate increased by 6.03%, as shares surge +27.95% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +15.08% upper at present.
During the last 5 trading sessions, BDTX rose by +6.74%, which changed the moving average for the period of 200-days by -61.13% in comparison to the 20-day moving average, which settled at $1.79. In addition, Black Diamond Therapeutics Inc saw -3.74% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BDTX starting from BIOTECH GROWTH N V, who sale 5,784,292 shares at the price of $2.07 back on Mar 19 ’25. After this action, BIOTECH GROWTH N V now owns 2,733,547 shares of Black Diamond Therapeutics Inc, valued at $11,997,749 using the latest closing price.
Versant Venture Capital VI, L., the 10% Owner of Black Diamond Therapeutics Inc, sale 221,600 shares at $6.32 during a trade that took place back on Aug 28 ’24, which means that Versant Venture Capital VI, L. is holding 3,726,341 shares at $1,400,556 based on the most recent closing price.
Stock Fundamentals for BDTX
The total capital return value is set at -0.03. Equity return is now at value 4.14, with 3.19 for asset returns.
Based on Black Diamond Therapeutics Inc (BDTX), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at 0.69.
Currently, EBITDA for the company is -69.33 million with net debt to EBITDA at 21.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.24.
Conclusion
To sum up, Black Diamond Therapeutics Inc (BDTX) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
